Last week, Heather Bresch, the CEO of Mylan Pharmaceuticals, testified in front of the US Congress about why the company has raised the price of EpiPen from roughly $US57 ($75) in 2007 to $US600 ($785) in the US today. (EpiPens are subsidised in Australia and typically under $100). Under intense questioning, she claimed that the company only makes about $US100 ($131) per two-pack of EpiPens. Today the company was forced to "clarify" that the price was actually higher. They make $US160 ($209).